Thermo Fisher Nears $10 Billion Acquisition of Clinical Trial Data Firm Clario

Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an all-cash acquisition of clinical trial data management company Clario in a deal valued at around $10 billion, according to the Financial Times. While Reuters has not yet confirmed the report, sources suggest the announcement could come as early as Wednesday, provided no last-minute complications arise.

If completed, this would mark Thermo Fisher’s largest acquisition since its $17.4 billion purchase of contract research organization PPD in 2021. The deal underscores Thermo Fisher’s strategic push to expand its footprint in clinical research and digital health data management, sectors that have seen accelerated growth in recent years.

Clario, established in 2021 through the merger of health tech companies ERT and Bioclinica, provides advanced software solutions that help pharmaceutical companies manage and analyze clinical trial data efficiently. The company’s investors include private equity firms Nordic Capital and Astorg. Clario’s technology plays a vital role in streamlining drug development processes, making it an attractive acquisition target amid growing demand for AI-driven healthcare solutions.

Neither Thermo Fisher nor Clario has commented on the reported deal. However, the acquisition aligns with Thermo Fisher’s ongoing strategy of strengthening its portfolio through high-value takeovers. Earlier in 2024, the company announced plans to acquire Solventum’s purification and filtration business for approximately $4.1 billion, further enhancing its capabilities in life sciences and laboratory technologies.

With increasing global demand for laboratory tools and integrated data solutions, Thermo Fisher recently raised its annual profit and revenue forecasts, signaling confidence in its growth trajectory. The potential Clario acquisition would not only expand Thermo Fisher’s reach in clinical research but also reinforce its position as a global leader in healthcare innovation and biotechnology.